MDS: a stem cell disorder--but what exactly is wrong with the primitive hematopoietic cells in this disease?
- PMID: 19074057
- DOI: 10.1182/asheducation-2008.1.43
MDS: a stem cell disorder--but what exactly is wrong with the primitive hematopoietic cells in this disease?
Abstract
Despite the various abnormalities identified in the immune system or the bone marrow microenvironment in patients with myelodysplastic syndrome (MDS), most of the investigation of this disorder has centered on the hematopoietic stem/progenitor compartment. It is generally written that MDS is a stem cell disorder, and there is certainly evidence supporting this view. However, whether it occurs in a cell with only myeloid multipotentiality (i.e., that involves megakaryocytic, erythroid and granulocytic/monocytic lineages) or occurs in a true stem cell is open to debate. The absence of an assay for human stem cells necessitates the use of surrogate markers for such cells, such as gene expression profiles, or the identification of specific genetic or epigenetic abnormalities that are found in multiple lineages. Clearly, the common cytogenetic and genetic abnormalities found in MDS are most indicative of a clonal myeloid disease similar to AML, rather than a lymphoid disease, and the often tri-lineage ineffective hematopoiesis and dysplasia are generally not found within the lymphoid compartment. Recent studies, using modern molecular detection techniques, have identified new recurring molecular lesions in these disorders but have not really unraveled its pathogenesis.
Similar articles
-
Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.Blood. 2017 Jan 26;129(4):484-496. doi: 10.1182/blood-2016-03-707745. Epub 2016 Nov 16. Blood. 2017. PMID: 27856460
-
The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.J Stem Cells. 2010;5(2):49-64. J Stem Cells. 2010. PMID: 22049615
-
Physician Education: Myelodysplastic Syndrome.Oncologist. 1996;1(4):284-287. Oncologist. 1996. PMID: 10388004
-
Stem cell origin of myelodysplastic syndromes.Oncogene. 2014 Oct 30;33(44):5139-50. doi: 10.1038/onc.2013.520. Epub 2013 Dec 16. Oncogene. 2014. PMID: 24336326 Review.
-
Bone marrow niche in the myelodysplastic syndromes.Leuk Res. 2015 Oct;39(10):1020-7. doi: 10.1016/j.leukres.2015.06.017. Epub 2015 Jul 14. Leuk Res. 2015. PMID: 26276090 Review.
Cited by
-
Azacitidine in the management of patients with myelodysplastic syndromes.Ther Adv Hematol. 2012 Dec;3(6):355-73. doi: 10.1177/2040620712464882. Ther Adv Hematol. 2012. PMID: 23606938 Free PMC article.
-
Sept4/ARTS is required for stem cell apoptosis and tumor suppression.Genes Dev. 2010 Oct 15;24(20):2282-93. doi: 10.1101/gad.1970110. Genes Dev. 2010. PMID: 20952537 Free PMC article.
-
Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes.Stem Cell Investig. 2014 Aug 21;1:16. doi: 10.3978/j.issn.2306-9759.2014.08.02. eCollection 2014. Stem Cell Investig. 2014. PMID: 27358862 Free PMC article. Review.
-
Effect of DLK1 on tumorigenesis in CD34+CD38- bone marrow cells in myelodysplastic syndromes.Oncol Lett. 2013 Jul;6(1):203-206. doi: 10.3892/ol.2013.1346. Epub 2013 May 14. Oncol Lett. 2013. PMID: 23946804 Free PMC article.
-
Functions and regulatory mechanisms of resting hematopoietic stem cells: a promising targeted therapeutic strategy.Stem Cell Res Ther. 2023 Apr 11;14(1):73. doi: 10.1186/s13287-023-03316-5. Stem Cell Res Ther. 2023. PMID: 37038215 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous